Vaxart (VXRT) Soars 30.73% on Positive Clinical Data

Vaxart (VXRT) surged 30.73% today, marking its third consecutive day of gains, with a cumulative increase of 78.67% over the past three days. The share price reached its highest level since January 2025, with an intraday gain of 44.44%.

VXRT's stock price reached a new high of $4.67 on June 11, 2025, following the announcement of promising Phase 1 results for its second-generation norovirus vaccine. To analyze the impact of this milestone on future price movements, we'll examine the stock's performance over the next 1 week, 1 month, and 3 months.

Next 1 Week: The stock surged by 70% on June 11, 2025, reaching its highest price of $4.67. Given the significant positive news event, it's likely that the stock could experience some consolidation or a pullback in the short term as investors digest the news and book profits. However, the overall sentiment remains positive, and the stock may maintain a relatively high level.

Next 1 Month: Historically, stocks that experience a significant price spike often experience some correction in the following days to weeks as the market rebalances. In VXRT's case, while there may be some consolidation, the positive long-term outlook for the vaccine candidate could support the stock price at a higher level than before the news event. The average target price of $4.67 suggests that analysts believe the stock has room to grow from its current level.

Next 3 Months: The stock's performance in the medium term will likely be influenced by the progress of the Phase 2b and Phase 3 trials, as well as any partnerships or funding announcements. The estimated GF Value of $77.97 for the stock in one year suggests a significant upside potential from the current price. However, it's important to note that market conditions and investor sentiment can also play a role in the stock's performance over this period.

In conclusion, while there may be some short-term consolidation, the overall trend for VXRT's stock price in the coming weeks and months is likely to be positive, supported by the strong vaccine candidate and the potential for further development and partnerships.

Vaxart held its Annual Meeting of Stockholders on June 13, 2025. During the meeting, stockholders voted against a proposal for a reverse stock split and against executive compensation plans. These decisions could have significant implications for the company's Nasdaq listing status and investor sentiment regarding management decisions, potentially influencing the stock price.

Vaxart reported positive clinical data from a Phase I trial, demonstrating that its second-generation vaccine technology produces stronger antibody responses compared to its first-generation technology. This advancement suggests potential for better protection against norovirus, positively impacting market potential and stock price. Despite the promising results, the stock experienced a significant plunge, indicating that other market factors or investor concerns may be affecting stock performance.